ADAPTIVE BIOTECHNOLOGIES CORPORATION
At today's price, ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) is priced for today's economics sustained for ~21.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Adaptive Biotechnologies runs two businesses, a commercial diagnostics arm built on its clonoSEQ test for measuring residual cancer in the blood, and an earlier-stage Immune Medicine research arm, and the diagnostics side is the engine: full-year 2025 MRD revenue grew 46% on clonoSEQ test volume up 39%. • The company is at the inflection from cash-burning to self-funding, guiding to positive adjusted EBITDA and positive free cash flow companywide in 2026, with sequencing gross margins above 70
Is ADPT overvalued? See what's priced in →
286 institutional managers reported holding ADPT in 13F filings for the quarter ended 2026-03-31. 46 opened new positions that quarter. Held by Viking Global, BlackRock, Vanguard Group, among others. On the short side, 7.6M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (2.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ADPT's share count grew 10.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ADPT over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ADPT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | -15.5% | -32.0% |
| 2023-11-10 | -22.2% | +25.4% |
| 2024-03-01 | +9.4% | -25.3% |
| 2024-05-08 | -1.2% | +10.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ADPT's latest 8-K filings: 2026-06-22 (items 1.01, 1.02, 2.03, 3.02, 8.01, 9.01); 2026-06-15 (items 8.01, 9.01); 2026-06-09 (items 5.07); 2026-05-05 (items 2.02, 9.01); 2026-02-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.